Kissei Pharmaceutical Co., Ltd.

TSE:4547 Stock Report

Market Cap: JP¥165.2b

Kissei Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Kissei Pharmaceutical has been growing earnings at an average annual rate of 24.1%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 3.4% per year. Kissei Pharmaceutical's return on equity is 4.9%, and it has net margins of 13.2%.

Key information

24.1%

Earnings growth rate

24.8%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate3.4%
Return on equity4.9%
Net Margin13.2%
Next Earnings Update03 Feb 2025

Recent past performance updates

Weak Statutory Earnings May Not Tell The Whole Story For Kissei Pharmaceutical (TSE:4547)

Nov 27
Weak Statutory Earnings May Not Tell The Whole Story For Kissei Pharmaceutical (TSE:4547)

Recent updates

Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥45.00

Jan 01
Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥45.00

Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00

Dec 18
Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00

Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00

Dec 04
Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00

Weak Statutory Earnings May Not Tell The Whole Story For Kissei Pharmaceutical (TSE:4547)

Nov 27
Weak Statutory Earnings May Not Tell The Whole Story For Kissei Pharmaceutical (TSE:4547)

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Sep 24
Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Sep 09
Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Jul 25
Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Jul 11
Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

May 21
Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

May 09
Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Mar 27
Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Mar 13
Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00

Feb 27
Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00

Revenue & Expenses Breakdown

How Kissei Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4547 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2481,06710,73124,1229,474
30 Jun 2477,43012,00134,0980
31 Mar 2475,57911,16020,7909,474
31 Dec 2373,71712,19819,79710,391
30 Sep 2371,60712,88019,76310,391
30 Jun 2370,52112,15820,23410,391
31 Mar 2367,49310,52820,30410,391
31 Dec 2266,93112,76920,42810,363
30 Sep 2265,85710,58121,55510,363
30 Jun 2265,03110,91220,36910,363
31 Mar 2265,38112,92119,92310,363
31 Dec 2166,9345,66421,6829,626
30 Sep 2169,1486,55520,7499,626
30 Jun 2169,6187,20420,5559,626
31 Mar 2169,0445,28519,6079,626
31 Dec 2066,8775,71518,40010,767
30 Sep 2063,9705,06318,82010,767
30 Jun 2063,1962,53019,77410,767
31 Mar 2063,2342,81721,13310,767
31 Dec 1965,5944,75317,51915,711
30 Sep 1968,1804,29421,03615,711
30 Jun 1970,5454,75222,08815,711
31 Mar 1972,2975,48122,57715,711
31 Dec 1872,4745,26324,21714,179
30 Sep 1873,0878,10220,84414,179
30 Jun 1873,0149,68520,77014,179
31 Mar 1874,0099,04523,08014,179
31 Dec 1773,8878,73524,17813,877
30 Sep 1772,4598,11624,74913,877
30 Jun 1771,3966,99325,15113,877
31 Mar 1771,7067,72623,37913,877
31 Dec 1672,1546,40125,19314,106
30 Sep 1673,5338,10823,51514,106
30 Jun 1673,7748,73422,45614,106
31 Mar 1671,2948,16522,52814,106
31 Dec 1571,2398,52121,78814,488
30 Sep 1569,0956,60822,54314,488
30 Jun 1570,9457,16123,40614,488
31 Mar 1570,1107,16522,41714,488
31 Dec 1469,6667,82923,78411,298
30 Sep 1473,0909,81723,69711,298
30 Jun 1469,9348,93523,05811,298
31 Mar 1470,3999,09322,78111,298

Quality Earnings: 4547 has a large one-off gain of ¥9.2B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 4547's current net profit margins (13.2%) are lower than last year (18%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4547's earnings have grown significantly by 24.1% per year over the past 5 years.

Accelerating Growth: 4547's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4547 had negative earnings growth (-16.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.6%).

Return on Equity

High ROE: 4547's Return on Equity (4.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 07:29
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kissei Pharmaceutical Co., Ltd. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ritsuo WatanabeBofA Global Research
Hidemaru YamaguchiCitigroup Global Markets Japan Inc.
Hidemaru YamaguchiCitigroup Inc